News | February 26, 2015

Cherenkov Effect Improves Radiation Therapy for Cancer Patients

Researchers say blue light can help calculate dosimetry of X-ray photons, protons and electrons

Cherenkov effect, radiation therapy, treatment planning, dosimetry

February 26, 2015 — Investigators from Dartmouth College’s Norris Cotton Cancer Center have discovered how the complex parts of the blue light known as the Cherenkov effect can be measured and used in dosimetry to make radiation therapies safer and more effective. Findings of the study, led by Brian W. Pogue, Ph.D., and Ph.D. candidates Adam K. Glaser and Rongxiao Zhang, were published in the journal Physics in Medicine and Biology.

"The beauty of using the light from the Cherenkov Effect for dosimetry is that it's the only current method that can reveal dosimetric information completely non-invasively in water or tissue," said Glaser.

Although the phenomenon has been constructively utilized for decades in high-energy particle and astrophysics, only recently has it been investigated during radiation therapy. In this study, investigators separately measured emissions of X-ray photons, protons and electrons, and they found widely varying utility.

Based on the findings of where dose correlates with Cherenkov emission, the Dartmouth team concluded that for X-ray photons, the light emission would be optimally suited for: narrow beam stereotactic radiation therapy and surgery validation studies; verification of dynamic intensity-modulated and volumetric modulated arc therapy treatment plans in water tanks; near mono-energetic sources (e.g., Co-60 and brachytherapy sources); and also for entrance and exit surface imaging dosimetry of both narrow and broad beams.

For electron use, Cherenkov emission was found to be suitable only for surface dosimetry applications. Finally, for proton dosimetry, there exists a fundamental lack of Cherenkov emission at the Bragg peak, making the technique of little use, although investigators say that post-irradiation detection of light emission from radioisotopes could prove to be useful.

"By detecting this light, we can pursue novel applications of Cherenkov light emission during radiation therapy to help clinicians improve the overall treatment outcome for patients," explained Pogue.

The collaborators intend to pursue further investigation at Norris Cotton Cancer Center to find other applications where this "free" light can be useful, such as continuing clinical trials in which the Cherenkov light from X-ray beams is imaged directly from a patient's tissue surface during radiation therapy.

For more information: www.cancer.dartmouth.edu

Related Content

With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.
RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ESTRO 2021, to be held in Madrid Aug. 27-30. Attendees will be able to book demonstrations of the RayStation treatment planning system, RayIntelligence the cloud-based oncology analytics system, and RayCare the oncology information system during the congress.
News | Radiation Oncology | August 30, 2021
August 30, 2021 — RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ...
RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) as a new modality that will one day treat all stages of cancer,announced the sale of its RefleXion X1 machine to The Center for Cancer and Blood Disorders, a free-standing cancer treatment center with 15 locations throughout northern Texas.

RefleXion Medical announces the sale of its X1 machine to The Center for Cancer and Blood Disorders in Texas. (Photo: Business Wire)

News | Radiation Therapy | August 23, 2021
August 23, 2021 — ...